A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback